Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · IEX Real-Time Price · USD
9.10
+0.11 (1.22%)
Apr 29, 2024, 4:30 PM EDT - Market closed
Elicio Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
93.01M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 28.31M | 25.43M | 883.06% |
| Dec 31, 2020 | 2.88M | 1.39M | 93.68% |
| Dec 31, 2019 | 1.49M | -2.54M | -63.09% |
| Dec 31, 2018 | 4.03M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| OptiNose | 70.99M |
| SHL Telemedicine | 57.08M |
| Allurion Technologies | 53.47M |
| Elutia | 24.75M |
| BioXcel Therapeutics | 1.38M |
| Barinthus Biotherapeutics | 802.00K |
| Genelux | 170.00K |
ELTX News
- 5 days ago - Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting - GlobeNewsWire
- 24 days ago - Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting - GlobeNewsWire
- 4 weeks ago - Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 6 weeks ago - Elicio Therapeutics Announces $6.0 Million Private Placement Financing - GlobeNewsWire
- 7 weeks ago - Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 3 months ago - Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors - GlobeNewsWire
- 3 months ago - Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium - GlobeNewsWire